Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Huse

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2011
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancersLuc G T Morris, Barry S Taylor, Trever G Bivona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid CellsPrajwal Rajappa, William S Cobb, Emma Vartanian, et al.
The Journal of Clinical Investigation|October 12, 2018
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic targetJun Wei, Anantha Marisetty, Brett Schrand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor ModelRupa Juthani, Brian Madajewski, Barney Yoo, et al.
Neuro-Oncology|October 10, 2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNicholas Butowski, Howard Colman, John F De Groot, et al.
Neuro-Oncology|August 21, 2023
Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeuticsPeter Kan, Visish M Srinivasan, Joy Gumin, et al.
The Journal of Clinical Investigation|April 11, 2017
A proangiogenic signaling axis in myeloid cells promotes malignant progression of gliomaYujie Huang, Prajwal Rajappa, Wenhuo Hu, et al.
Neuro-Oncology|August 10, 2024
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomasPravesh Gupta, Minghao Dang, Shivangi Oberai, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2011
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancersLuc G T Morris, Barry S Taylor, Trever G Bivona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid CellsPrajwal Rajappa, William S Cobb, Emma Vartanian, et al.
The Journal of Clinical Investigation|October 12, 2018
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic targetJun Wei, Anantha Marisetty, Brett Schrand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor ModelRupa Juthani, Brian Madajewski, Barney Yoo, et al.
Neuro-Oncology|October 10, 2015
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II studyNicholas Butowski, Howard Colman, John F De Groot, et al.
Neuro-Oncology|August 21, 2023
Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeuticsPeter Kan, Visish M Srinivasan, Joy Gumin, et al.
The Journal of Clinical Investigation|April 11, 2017
A proangiogenic signaling axis in myeloid cells promotes malignant progression of gliomaYujie Huang, Prajwal Rajappa, Wenhuo Hu, et al.
Neuro-Oncology|August 10, 2024
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomasPravesh Gupta, Minghao Dang, Shivangi Oberai, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Pageof 4